Celularity (CELU) AI Stock Analysis

• Market Cap: $45.91M
• Dividend Yield: N/A
• Average Volume (3M): 206.82K
• Price to Earnings (P/E): ―
• Beta (1Y): 3.20
• Revenue Growth: 4.45%
• EPS Growth: 45.19%
• Country: US
• Employees: 120
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.02
• Shares Outstanding: 26,691,477
• 10 Day Avg. Volume: 277,262
• 30 Day Avg. Volume: 206,824
• PEG Ratio: 0.01
• Price to Book (P/B): 5.15
• Price to Sales (P/S): 0.84
• P/FCF Ratio: -6.94
• Enterprise Value/Market Cap: 2.53
• Enterprise Value/Revenue: 2.61
• Enterprise Value/Gross Profit: 4.74
• Enterprise Value/Ebitda: -2.00
• 1Y Price Target: $6.00
• Price Target Upside: 287.10% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $1.50 ▼(-3.23% Downside)

Celularity's stock score is primarily impacted by its weak financial performance, characterized by high leverage, declining equity, and ongoing losses. The technical analysis indicates a bearish trend, with the stock trading below key moving averages and technical indicators suggesting oversold conditions. Valuation metrics are unfavorable due to negative earnings and lack of dividends, further weighing down the overall score.

Positive Factors

Strategic Partnership

This partnership with DefEYE enhances Celularity's market reach in regenerative therapies for eye care, potentially opening new revenue streams and strengthening its competitive position in the biotechnology sector.

Revenue Growth

The significant revenue growth indicates strong demand for Celularity's therapies, suggesting successful market penetration and potential for sustained financial improvement.

Gross Profit Margin Improvement

The improvement in gross profit margin reflects enhanced operational efficiency, which could lead to better profitability if the trend continues.

Negative Factors

High Leverage

High leverage indicates financial risk, potentially limiting Celularity's ability to invest in growth opportunities and increasing vulnerability to economic downturns.

Negative Cash Flow

Despite improvements, ongoing negative cash flow suggests Celularity may struggle to fund operations without external financing, posing a risk to long-term sustainability.

Declining Equity

Declining equity indicates potential financial instability, reducing the company's buffer against losses and limiting its ability to secure favorable financing terms.

Celularity Business Overview & Revenue Model

Company Description

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

How the Company Makes Money

Celularity generates revenue primarily through the development and commercialization of its cell-based therapies. Key revenue streams include upfront payments, milestone payments, and royalties from partnerships with pharmaceutical companies and research institutions. The company may also earn revenue through licensing agreements for its proprietary technologies and products. Significant partnerships with larger biotech and pharmaceutical companies enhance its capabilities and market reach, contributing to its earnings through collaborative research and development agreements.

Celularity Financial Statement Overview

Summary

Celularity is experiencing robust revenue growth, yet profitability remains a challenge with substantial losses. The balance sheet indicates high leverage and declining equity, raising concerns about financial stability. Cash flows are negative but improving slightly, supported by financing activities. The company needs to focus on improving profitability and managing debt to enhance its financial health.

Income Statement

Celularity has shown a significant increase in revenue, growing from $22.8 million in 2023 to $54.2 million in 2024. However, the company remains unprofitable with a negative net profit margin due to high operational expenses, as indicated by negative EBIT and EBITDA margins. The gross profit margin improved to 83.6% in 2024 from 29.7% in 2023, which is a positive sign of operational efficiency.

Balance Sheet

The balance sheet reveals high leverage with a debt-to-equity ratio of 3.29 in 2024, indicating financial risk. The equity ratio is low at 6.7%, showing limited equity buffer. The stockholders' equity has decreased significantly, reflecting potential financial instability and risk.

Cash Flow

Celularity's free cash flow remains negative, but has improved from -$42.7 million in 2023 to -$6.56 million in 2024. The operating cash flow to net income ratio is negative, highlighting ongoing cash drain. However, the company successfully raised funds through financing activities, providing some liquidity cushion.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.59M	54.22M	22.77M	17.98M	21.34M	14.28M
Gross Profit	24.57M	39.23M	6.75M	-1.69M	11.68M	9.35M
EBITDA	-58.29M	-43.71M	-183.95M	23.58M	-88.11M	-202.41M
Net Income	-73.67M	-57.89M	-196.29M	14.19M	-100.12M	-208.23M
Balance Sheet
Total Assets	120.28M	132.68M	143.89M	401.07M	414.13M	431.01M
Cash, Cash Equivalents and Short-Term Investments	863.00K	738.00K	227.00K	13.97M	37.24M	54.31M
Total Debt	70.15M	68.84M	65.42M	65.59M	31.14M	30.64M
Total Liabilities	145.78M	123.84M	102.93M	202.16M	314.71M	962.41M
Stockholders Equity	-25.50M	8.84M	40.96M	198.90M	99.42M	-531.40M
Cash Flow
Free Cash Flow	-2.63M	-6.56M	-42.73M	-143.11M	-116.30M	-91.03M
Operating Cash Flow	-2.54M	-6.40M	-38.69M	-137.88M	-110.10M	-63.19M
Investing Cash Flow	-1.59M	514.00K	-4.05M	-5.24M	-5.90M	-12.81M
Financing Cash Flow	4.51M	6.70M	24.09M	119.84M	98.56M	102.01M

Celularity Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.55
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Negative. The current price of 1.55 is below the 20-day moving average (MA) of 1.85, below the 50-day MA of 2.03, and below the 200-day MA of 2.13, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 32.07 is Neutral, neither overbought nor oversold. The STOCH value of 11.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CELU.

Celularity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
STTK	49 Neutral	$121.88M	-1.60	-57.84%	―	-84.46%	33.32%
RPTX	47 Neutral	$76.47M	-0.69	-69.96%	―	-99.64%	-59.17%
LTRN	45 Neutral	$39.20M	-2.03	-104.58%	―	―	1.18%
GBIO	41 Neutral	$35.36M	-0.48	-80.81%	―	-17.82%	57.32%
FBLG	38 Underperform	$16.83M	-0.68	-1292.87%	―	―	18.47%
CELU	38 Underperform	$45.91M	-0.54	-6367.24%	―	4.45%	45.19%

Celularity Corporate Events

Celularity Secures $2 Million in Private Placement

On October 24, 2025, Celularity Inc. entered into a Securities Purchase Agreement with an institutional investor to issue and sell Series A Convertible Preferred Stock and accompanying warrants in a private placement transaction. The initial tranche closed on the same day, providing the company with approximately $2 million in gross proceeds. The funds are intended for working capital and general corporate purposes, potentially impacting the company’s financial flexibility and market operations. The agreement includes provisions for conversion, voting rights, and dividend entitlements, with implications for shareholder equity and market positioning.

The most recent analyst rating on (CELU) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.

Celularity Achieves Nasdaq Compliance with Recent Filing

On September 2, 2025, Nasdaq informed Celularity Inc. that the company is in compliance with Listing Rule 5250(c)(1), following the filing of its Form 10-Q for the periods ending March 31, 2025, and June 30, 2025. This resolution closes the matter, indicating that Celularity has met the necessary regulatory requirements, which may positively impact its market standing and reassure stakeholders.

The most recent analyst rating on (CELU) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.

Celularity Sells IP to Celeniv, Reduces Debt

On August 13, 2025, Celularity Inc. entered into an asset purchase agreement with Celeniv Pte. Ltd., selling certain intellectual property for $33,812,230, which was used to retire all senior secured debt. The agreement included a license back of the IP to Celularity with a five-year repurchase option. This restructuring eliminated $41.6 million in debt, improved financial flexibility, and led to the creation of four wholly-owned subsidiaries to enhance operational efficiency across its commercial units.

The most recent analyst rating on (CELU) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Celularity stock, see the CELU Stock Forecast page.

Celularity Enters Series Seed Stock Agreement with Defeye

Celularity Inc. entered into a Series Seed Preferred Stock Purchase Agreement with Defeye, Inc. on August 5, 2025, involving the issuance of 7,198.630 shares of Series Seed-2 Preferred Stock in exchange for $2,890,250 of product purchase credits. Additionally, Celularity faced compliance issues with Nasdaq due to a delay in filing its quarterly report for the quarter ended March 31, 2025. The company submitted a compliance plan on August 1, 2025, and was given until August 31, 2025, to file the necessary reports to avoid delisting.